Deficiency of ARID1A has been described to be associated with an increased programmed cell death-ligand 1 (PD-L1) expression, a high tumor mutational burden (TMB), impaired mismatch repair (MMR) and a modulated tumor microenvironment. This evidence concerns the gene ARID1A and neoplasm.